![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Elysee Development Corp (PK) | USOTC:ASXSF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04154 | 21.12% | 0.23824 | 0.193 | 0.3345 | 0.23824 | 0.23824 | 0.23824 | 1,106 | 21:00:35 |
Nevada
|
|
86-0837251
|
(State or Other Jurisdiction
Of Incorporation or Organization)
|
|
(I.R.S. Employer Identification
Number)
|
|
|
|
Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium
|
|
N/A
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Large accelerated filer
|
¨
|
Accelerated filer
|
¨
|
|
|
|
|
Non-accelerated filer
|
¨
|
Smaller reporting company
|
x
|
(Do not check if a smaller reporting company)
|
1 | ||
|
|
|
For the three months ended
December 31, |
|
For the nine months ended
December 31, |
|
||||||||
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
865,897
|
|
$
|
723,952
|
|
$
|
2,332,007
|
|
$
|
1,572,511
|
|
Cost of sales
|
|
|
230,914
|
|
|
356,356
|
|
|
748,065
|
|
|
870,801
|
|
Gross profit
|
|
|
634,983
|
|
|
367,596
|
|
|
1,583,942
|
|
|
701,710
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
23,535
|
|
|
14,509
|
|
|
59,820
|
|
|
43,948
|
|
Sales and marketing
|
|
|
173,927
|
|
|
223,570
|
|
|
519,930
|
|
|
569,869
|
|
General and administrative
|
|
|
381,160
|
|
|
571,464
|
|
|
936,167
|
|
|
1,743,363
|
|
Depreciation and amortization
|
|
|
60,382
|
|
|
73,334
|
|
|
179,685
|
|
|
246,451
|
|
TOTAL OPERATING EXPENSES
|
|
|
639,004
|
|
|
882,877
|
|
|
1,695,602
|
|
|
2,603,631
|
|
INCOME (LOSS) FROM OPERATIONS
|
|
|
(4,021)
|
|
|
(515,281)
|
|
|
(111,660)
|
|
|
(1,901,921)
|
|
OTHER INCOME (EXPENSES)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of Remedent OTC B.V.
|
|
|
|
|
|
|
|
|
|
|
|
521,159
|
|
Equity income from investments
|
|
|
59,997
|
|
|
126,291
|
|
|
261,522
|
|
|
119,376
|
|
Interest expense
|
|
|
(31,651)
|
|
|
(56,555)
|
|
|
(87,526)
|
|
|
(153,811)
|
|
Other income
|
|
|
91,743
|
|
|
14,899
|
|
|
101,918
|
|
|
21,171
|
|
Other expense
|
|
|
(5,123)
|
|
|
(4,715)
|
|
|
(11,604)
|
|
|
(10,382)
|
|
TOTAL OTHER INCOME (EXPENSES)
|
|
|
114,966
|
|
|
79,920
|
|
|
264,310
|
|
|
497,513
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET INCOME (LOSS) BEFORE INCOME TAXES
|
|
|
110,945
|
|
|
(435,361)
|
|
|
152,650
|
|
|
(1,404,408)
|
|
PROVISION FOR INCOME TAXES
|
|
|
|
|
|
(153)
|
|
|
|
|
|
(153)
|
|
NET INCOME (LOSS)
|
|
$
|
110,945
|
|
$
|
(435,514)
|
|
$
|
152,650
|
|
$
|
(1,404,561)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME (LOSS) PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.01
|
|
$
|
(0.02)
|
|
$
|
0.01
|
|
$
|
(0.07)
|
|
Fully diluted
|
|
$
|
0.01
|
|
$
|
(0.02)
|
|
$
|
0.01
|
|
$
|
(0.07)
|
|
WEIGHTED AVERAGE SHARES OUTSTANDING
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
19,995,969
|
|
|
19,995,969
|
|
|
19,995,969
|
|
|
19,995,969
|
|
Fully diluted
|
|
|
19,995,969
|
|
|
19,995,969
|
|
|
19,995,969
|
|
|
19,995,969
|
|
2 | ||
|
|
|
For the three months ended
December 31, |
|
For the nine months ended
December 31, |
|
||||||||
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
||||
NET INCOME (LOSS)
|
|
$
|
110,945
|
|
$
|
(435,514)
|
|
$
|
152,650
|
|
$
|
(1,404,561)
|
|
OTHER COMPREHENSIVE INCOME (LOSS):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
11,893
|
|
|
(28,082)
|
|
|
24,078
|
|
|
79,005
|
|
COMPREHENSIVE INCOME (LOSS)
|
|
$
|
122,838
|
|
$
|
(463,596)
|
|
$
|
176,728
|
|
$
|
(1,325,556)
|
|
3 | ||
|
|
|
For the nine months ended
December 31, |
|
||||
|
|
2013
|
|
2012
|
|
||
|
|
|
|
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
152,650
|
|
$
|
(1,404,561)
|
|
Adjustments to reconcile net income (loss) to net cash used by operating activities
|
|
|
|
|
|
|
|
Gain on sale of Remedent OTC B.V.
|
|
|
|
|
|
(521,159)
|
|
Depreciation and amortization
|
|
|
179,685
|
|
|
246,451
|
|
Inventory reserve
|
|
|
5,951
|
|
|
(751)
|
|
Allowance for doubtful accounts
|
|
|
324
|
|
|
(7,372)
|
|
Equity investment
|
|
|
(261,522)
|
|
|
(119,376)
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
64,562
|
|
|
220,102
|
|
Inventories
|
|
|
17,289
|
|
|
16,927
|
|
Prepaid expenses
|
|
|
351,593
|
|
|
415,602
|
|
Accounts payable
|
|
|
136,954
|
|
|
52,763
|
|
Accrued liabilities
|
|
|
(293,762)
|
|
|
(69,267)
|
|
Accrued and unpaid interest on debt
|
|
|
|
|
|
17,672
|
|
Due to related parties
|
|
|
145,188
|
|
|
(20,470)
|
|
Deferred revenue
|
|
|
(50,891)
|
|
|
136,530
|
|
Net cash provided by operating activities
|
|
|
448,021
|
|
|
(1,036,909)
|
|
CASH FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
Proceeds on sale of Remedent OTC B.V.
|
|
|
|
|
|
667,300
|
|
Purchases of patent rights
|
|
|
(2,436)
|
|
|
(31,598)
|
|
Purchases of equipment
|
|
|
(62,859)
|
|
|
(112,091)
|
|
Net cash used by investing activities
|
|
|
(65,295)
|
|
|
523,611
|
|
CASH FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
Loans payable
|
|
|
|
|
|
132,820
|
|
Net (repayments of) capital leases and notes payable
|
|
|
(67,076)
|
|
|
(76,799)
|
|
(Repayments of) proceeds from line of credit
|
|
|
(292,647)
|
|
|
378,591
|
|
Net cash provided by financing activities
|
|
|
(359,723)
|
|
|
434,612
|
|
NET (DECREASE) INCREASE IN CASH
|
|
|
23,003
|
|
|
(78,686)
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
11,885
|
|
|
(111,908)
|
|
CASH AND CASH EQUIVALENTS, BEGINNING
|
|
|
64,504
|
|
|
203,584
|
|
CASH AND CASH EQUIVALENTS, ENDING
|
|
$
|
99,392
|
|
$
|
12,990
|
|
Supplemental Information:
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
49,855
|
|
$
|
124,093
|
|
Income taxes paid
|
|
$
|
|
|
$
|
|
|
4 | ||
|
1.
|
DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION
|
|
2.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
5 | ||
|
|
|
Nine months
ended December 31, 2013 |
|
Year ended
March 31, 2013 |
|
||
Product warranty liability:
|
|
|
|
|
|
|
|
Opening balance
|
|
$
|
19,301
|
|
$
|
20,019
|
|
Accruals for product warranties issued in the period
|
|
|
|
|
|
(973)
|
|
Adjustments to liabilities for pre-existing warranties
|
|
|
1,294
|
|
|
255
|
|
Ending liability
|
|
$
|
20,595
|
|
$
|
19,301
|
|
6 | ||
|
7 | ||
|
|
GLAMSMILE ASIA LTD.
|
|
1.
|
325,000
Euro (US$
466,725
). As of March 31, 2011 the full amount was paid.
|
|
2.
|
250,000
shares of common stock to be issued during the fiscal year ended March 31, 2011 ($
97,500
was recorded as an obligation to issue shares as at March 31, 2010). The parties have agreed that the shares will be issued during fiscal year ended March 31, 2014.
|
|
3.
|
100,000
options on closing (issued);
|
|
4.
|
100,000
options per opened store at closing (issued);
|
|
5.
|
100,000
options for each additional store opened before the end of 2011 at the price of the opening date of the store;
|
|
6.
|
Assumption of Glamsmile’s January 1, 2010 deficit of $
73,302
.; and
|
|
7.
|
Repayment of the founding shareholder’s original advances in the amount of $
196,599
. The balance of $
196,599
, recorded as due to related parties at March 31, 2010, is unsecured, non-interest bearing and has no specific terms of repayment other than it will be paid out of revenues from Glamsmile, as working capital allows. During the year ended March 31, 2011 a total of $
101,245
was paid to the founding shareholder, leaving a balance due of $
95,354
on June 27, 2011. As at March 31, 2012 the full amount was paid.
|
8 | ||
|
Consideration received
|
|
$
|
2,000,000
|
|
Fair value of 29.4% interest
|
|
|
2,055,884
|
|
Carrying value of non-controlling interest
|
|
|
1,117,938
|
|
Less: carrying value of former subsidiary’s net assets
|
|
|
(2,002,329)
|
|
Goodwill
|
|
|
(699,635)
|
|
Investment China & Hong Kong
|
|
|
(1,082)
|
|
Rescission agreement Excelsior (Note 11)
|
|
|
(1,000,000)
|
|
|
|
$
|
1,470,776
|
|
9 | ||
|
|
4.
|
SHORT TERM LOAN
|
5.
|
CONCENTRATION OF RISK
|
6.
|
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
|
|
|
December 31,
2013 |
|
March 31, 2013
|
|
||
Accounts receivable, gross
|
|
$
|
888,566
|
|
$
|
952,804
|
|
Less: allowance for doubtful accounts
|
|
|
(5,157)
|
|
|
(4,833)
|
|
Accounts receivable, net
|
|
$
|
883,409
|
|
$
|
947,971
|
|
|
7.
|
INVENTORIES
|
|
|
December 31,
2013 |
|
March 31, 2013
|
|
||
Raw materials
|
|
$
|
30,018
|
|
$
|
38,452
|
|
Components
|
|
|
200,904
|
|
|
214,723
|
|
Finished goods
|
|
|
838,271
|
|
|
827,356
|
|
|
|
|
1,069,193
|
|
|
1,080,531
|
|
Less: reserve for obsolescence
|
|
|
(94,675)
|
|
|
(88,724)
|
|
Net inventory
|
|
$
|
974,518
|
|
$
|
991,807
|
|
10 | ||
|
|
8.
|
PREPAID EXPENSES
|
|
|
December 31,
2013 |
|
March 31, 2013
|
|
||
Prepaid materials and components
|
|
$
|
45,321
|
|
$
|
196,876
|
|
Prepaid Consulting
|
|
|
|
|
|
73,854
|
|
VAT payments in excess of VAT receipts
|
|
|
16,427
|
|
|
41,241
|
|
Prepaid trade show expenses
|
|
|
|
|
|
4,632
|
|
Prepaid rent
|
|
|
128,375
|
|
|
129,957
|
|
Other
|
|
|
24,784
|
|
|
119,940
|
|
|
|
$
|
214,907
|
|
$
|
566,500
|
|
|
9.
|
PROPERTY AND EQUIPMENT
|
|
|
December 31,
2013 |
|
March 31, 2013
|
|
||
Furniture and Fixtures
|
|
$
|
599,950
|
|
$
|
596,471
|
|
Machinery and Equipment
|
|
|
1,679,149
|
|
|
1,619,770
|
|
|
|
|
2,279,099
|
|
|
2,216,241
|
|
Accumulated depreciation
|
|
|
(1,679,694)
|
|
|
(1,521,157)
|
|
Property & equipment, net
|
|
$
|
599,405
|
|
$
|
695,084
|
|
|
10.
|
LINE OF CREDIT
|
Year ending March 31:
|
|
$
|
|
|
|
|
|
|
|
2014
|
|
|
20,708
|
|
2015
|
|
|
83,509
|
|
2016
|
|
|
|
|
Later years
|
|
|
|
|
Total minimum lease payments
|
|
|
104,217
|
|
Less: Amount representing estimated executory costs (such as taxes, maintenance, and insurance), including profit thereon, included in total minimum lease payments
|
|
|
|
|
Net minimum lease payments
|
|
|
104,217
|
|
Less: Amount representing interest (*)
|
|
|
2,419
|
|
Present value of minimum lease payments (**)
|
|
$
|
101,798
|
|
12.
|
DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS
|
12 | ||
|
|
13.
|
ACCRUED LIABILITIES
|
|
|
December 31,
2013 |
|
March 31, 2013
|
|
||
Accrued employee benefit taxes and payroll
|
|
$
|
316,246
|
|
$
|
397,666
|
|
Accrued travel
|
|
|
6,865
|
|
|
9,650
|
|
Accrued audit and tax preparation fees
|
|
|
15,186
|
|
|
14,264
|
|
Reserve for warranty costs
|
|
|
20,595
|
|
|
19,301
|
|
Advances received on account
|
|
|
|
|
|
11,823
|
|
Accrued advertising
|
|
|
7,438
|
|
|
9,864
|
|
Accrued interest
|
|
|
3,433
|
|
|
12,578
|
|
Accrued consulting fees
|
|
|
1,500
|
|
|
2,500
|
|
Other accrued expenses
|
|
|
72,039
|
|
|
259,418
|
|
|
|
$
|
443,302
|
|
$
|
737,064
|
|
|
14.
|
EQUITY COMPENSATION PLANS
|
|
|
2001 Plan
|
|
2004 Plan
|
|
2007 Plan
|
|
Other
|
|
||||||||||||||||
|
|
Outstanding
Options |
|
Weighted
Average Exercise Price |
|
Outstanding
Options |
|
Weighted
Average Exercise Price |
|
Outstanding
Options |
|
Weighted
Average Exercise Price |
|
Outstanding
Options |
|
Weighted
Average Exercise Price |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, March 31, 2013
|
|
|
12,500
|
|
|
2.00
|
|
|
432,500
|
|
|
0.96
|
|
|
1,000,000
|
|
|
1.21
|
|
|
350,000
|
|
|
0.97
|
|
Options outstanding and exercisable December 31, 2013
|
|
|
12,500
|
|
|
2.00
|
|
|
432,500
|
|
|
0.96
|
|
|
1,000,000
|
|
|
1.21
|
|
|
350,000
|
|
|
0.97
|
|
Exercise price range
|
|
$
|
2.00
|
|
|
|
|
|
$0.50 - $2.46
|
|
|
|
|
|
$0.50 - $1.75
|
|
|
|
|
|
$0.39 - 1.75
|
|
|
|
|
Weighted average remaining life
|
|
|
0.27 years
|
|
|
|
|
|
4.65 years
|
|
|
|
|
|
4.37 years
|
|
|
|
|
|
2.8 years
|
|
|
|
|
13 | ||
|
Plan Category
|
|
Number of
securities to be issued upon exercise of of outstanding options, warrants and rights |
|
Weighted-average
exercise price of outstanding options warrants and rights |
|
Number of
securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
|
|||
Equity Compensation Plans approved by security holders
|
|
|
1,445,000
|
|
$
|
1.17
|
|
|
605,000
|
|
Equity Compensation Plans not approved by security holders
|
|
|
820,000
|
|
$
|
.97
|
|
|
NA
|
|
Total
|
|
|
2,265,000
|
|
$
|
1.10
|
|
|
605,000
|
|
|
15.
|
COMMON STOCK WARRANTS AND OTHER OPTIONS
|
|
|
Outstanding
Warrants |
|
Weighted
Average Exercise Price |
|
||
Warrants outstanding and exercisable March 31, 2013
|
|
|
3,738,379
|
|
$
|
1.40
|
|
Expired in the period
|
|
|
(3,738,379)
|
|
|
|
|
Warrants outstanding and exercisable December 31, 2013
|
|
|
|
|
|
|
|
|
16.
|
SEGMENT INFORMATION
|
|
17.
|
COMMITMENTS
|
March 31, 2014
|
|
|
108,826
|
|
March 31, 2015
|
|
|
387,423
|
|
March 31, 2016
|
|
|
291,542
|
|
March 31, 2017
|
|
|
251,160
|
|
After five years
|
|
|
144,237
|
|
Total:
|
|
$
|
1,183,188
|
|
18.
|
FINANCIAL INSTRUMENTS
|
|
|
|
|
|
December 31, 2013
|
|
March 31, 2013
|
|
||||||||
|
|
|
|
|
Carrying
|
|
Fair
|
|
Carrying
|
|
Fair
|
|
||||
|
|
Level
|
|
Value
|
|
Value
|
|
value
|
|
value
|
|
|||||
Cash
|
|
|
1
|
|
$
|
99,392
|
|
$
|
99,392
|
|
$
|
64,504
|
|
$
|
64,504
|
|
Accounts receivable
|
|
|
2
|
|
$
|
883,409
|
|
$
|
883,409
|
|
$
|
947,971
|
|
$
|
947,971
|
|
Long Term investment and advance - GlamSmile Dental Technology Asia
|
|
|
2
|
|
$
|
2,703,094
|
|
$
|
2,703,094
|
|
$
|
2,441,572
|
|
$
|
2,441,572
|
|
Long term investments and advances MFI
|
|
|
2
|
|
$
|
787,339
|
|
$
|
787,339
|
|
$
|
787,339
|
|
$
|
787,339
|
|
Line of credit
|
|
|
2
|
|
$
|
543,708
|
|
$
|
543,708
|
|
$
|
836,355
|
|
$
|
836,355
|
|
Short term debt
|
|
|
2
|
|
$
|
2,147,190
|
|
$
|
2,147,190
|
|
$
|
1,214,266
|
|
$
|
1,214,266
|
|
Deferred revenue
|
|
|
2
|
|
$
|
98,238
|
|
$
|
98,238
|
|
$
|
149,129
|
|
$
|
149,129
|
|
Accounts payable
|
|
|
2
|
|
$
|
1,112,201
|
|
$
|
1,112,201
|
|
$
|
971,813
|
|
$
|
971,813
|
|
Accrued liabilities
|
|
|
2
|
|
$
|
443,302
|
|
$
|
443,302
|
|
$
|
737,064
|
|
$
|
737,064
|
|
Long term debt
|
|
|
2
|
|
$
|
131,364
|
|
$
|
131,364
|
|
$
|
1,131,364
|
|
$
|
1,131,364
|
|
15 | ||
|
|
|
Nine month period ended
December 31, 2013 |
|
|
Long term investments and advances:
|
|
|
|
|
Beginning balance
|
|
$
|
2,441,572
|
|
Gains (losses) included in net loss
|
|
|
261,522
|
|
Transfers in (out of level 3)
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
2,703,094
|
|
|
|
For the three months ended
December 31, |
|
|
For the nine months ended
December 31, |
|
|
||||||||||
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET SALES
|
|
|
100.00
|
%
|
|
|
100.00
|
%
|
|
|
100.00
|
%
|
|
|
100.00
|
%
|
|
COST OF SALES
|
|
|
26.67
|
%
|
|
|
49.22
|
%
|
|
|
32.08
|
%
|
|
|
55.38
|
%
|
|
GROSS PROFIT
|
|
|
73.33
|
%
|
|
|
50.78
|
%
|
|
|
67.92
|
%
|
|
|
44.62
|
%
|
|
OPERATING EXPENSES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
2.72
|
%
|
|
|
2.00
|
%
|
|
|
2.57
|
%
|
|
|
2.79
|
%
|
|
Sales and marketing
|
|
|
20.09
|
%
|
|
|
30.88
|
%
|
|
|
22.30
|
%
|
|
|
36.24
|
%
|
|
General and administrative
|
|
|
44.02
|
%
|
|
|
78.94
|
%
|
|
|
40.14
|
%
|
|
|
110.86
|
%
|
|
Depreciation and amortization
|
|
|
6.97
|
%
|
|
|
10.13
|
%
|
|
|
7.71
|
%
|
|
|
15.67
|
%
|
|
TOTAL OPERATING EXPENSES
|
|
|
73.80
|
%
|
|
|
121.95
|
%
|
|
|
72.71
|
%
|
|
|
165.57
|
%
|
|
INCOME (LOSS) FROM OPERATIONS
|
|
|
(0.46)
|
%
|
|
|
(71.18)
|
%
|
|
|
(4.79)
|
%
|
|
|
(120.95)
|
%
|
|
Other income (expense)
|
|
|
13.28
|
%
|
|
|
11.04
|
%
|
|
|
11.33
|
%
|
|
|
31.64
|
%
|
|
NET INCOME (LOSS) BEFORE TAXES
|
|
|
12.81
|
%
|
|
|
(60.14)
|
%
|
|
|
6.55
|
%
|
|
|
(89.31)
|
%
|
|
INCOME TAXES
|
|
|
(0.00)
|
%
|
|
|
(0.02)
|
%
|
|
|
(0.00)
|
%
|
|
|
(0.01)
|
%
|
|
NET INCOME (LOSS)
|
|
|
12.81
|
%
|
|
|
(60.16)
|
%
|
|
|
6.55
|
%
|
|
|
(89.32)
|
%
|
|
17 | ||
|
18 | ||
|
19 | ||
|
20 | ||
|
Exhibit No
|
|
Description
|
|
|
|
31.1*
|
|
Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act
|
|
|
|
31.2*
|
|
Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act
|
|
|
|
32.1*
|
|
Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act
|
|
|
|
32.2*
|
|
Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act
|
|
|
|
101.INS**
|
|
XBRL Instance Document
|
|
|
|
101.SCH**
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
101.CAL**
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
|
101.DEF**
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
|
101.LAB**
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
|
101.PRE**
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
21 | ||
|
|
REMEDENT, INC.
|
|
|
|
|
Date: February
14, 2014
|
By:
|
/s/ Guy De Vreese
|
|
|
Name: Guy De Vreese
|
|
|
Title: Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
Date: February
14, 2014
|
By:
|
/s/ Philippe Van Acker
|
|
|
Name: Philippe Van Acker
|
|
|
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)
|
22 | ||
|
1 Year Elysee Development (PK) Chart |
1 Month Elysee Development (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions